Can a simple blood test predict chemo success in rare cancer?
NCT ID NCT05653388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood and tumor samples from 200 people with metastatic leiomyosarcoma who are starting chemotherapy. Researchers will analyze circulating tumor DNA (ctDNA) and genetic changes to see if they can predict how well the chemotherapy works. Participants also fill out a questionnaire about genetics. The goal is to find early biomarkers that could guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify early markers in the blood that show whether chemotherapy is working, helping doctors tailor treatment sooner.
What could go wrong
This is an observational study, not a treatment trial. It may not find reliable biomarkers, and results may not change current care for years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
Contact Email: •••••@•••••
-
Dana- Farber
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55901, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Email: •••••@•••••
-
Sarcoma Oncology Research Center
RECRUITINGSanta Monica, California, 90403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact
-
University of Michigan Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-••••
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-••••